Investigational Drug Information for Indobufen
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Indobufen?
Indobufen is an investigational drug.
There have been 8 clinical trials for Indobufen.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 17th 2019.
The most common disease conditions in clinical trials are Coronary Artery Disease, Myocardial Ischemia, and Atherosclerosis. The leading clinical trial sponsors are The First Affiliated Hospital with Nanjing Medical University, NicOx Research Institute S.r.l., and Ministry of Science and Technology of the People´s Republic of China.
There are two hundred and eleven US patents protecting this investigational drug and two international patents.
Summary for Indobufen
| US Patents | 211 |
| International Patents | 2,584 |
| US Patent Applications | 580 |
| WIPO Patent Applications | 324 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 3 (2019-10-17) |
| Vendors | 68 |
Recent Clinical Trials for Indobufen
| Title | Sponsor | Phase |
|---|---|---|
| Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Coronary Heart Disease | Henan Institute of Cardiovascular Epidemiology | N/A |
| A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis | The First Affiliated Hospital with Nanjing Medical University | Phase 4 |
| GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet Therapy | Beijing Anzhen Hospital | Phase 4 |
Clinical Trial Summary for Indobufen
Top disease conditions for Indobufen
Top clinical trial sponsors for Indobufen
US Patents for Indobufen
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Indobufen | See Plans and Pricing | Analyte sensor | DexCom, Inc. (San Diego, CA) | See Plans and Pricing |
| Indobufen | See Plans and Pricing | WT1 peptide cancer vaccine composition for transdermal administration | NITTO DENKO CORPORATION (Osaka, JP) OSAKA UNIVERSITY (Osaka, JP) | See Plans and Pricing |
| Indobufen | See Plans and Pricing | Vaccine composition | NITTO DENKO CORPORATION (Osaka, JP) | See Plans and Pricing |
| Indobufen | See Plans and Pricing | Heterogeneous implantable devices for drug delivery | TITAN PHARMACEUTICALS, INC. (South San Francisco, CA) | See Plans and Pricing |
| Indobufen | See Plans and Pricing | Heterogeneous implantable devices for drug delivery | Titan Pharmaceuticals, Inc. (South San Francisco, CA) | See Plans and Pricing |
| Indobufen | See Plans and Pricing | Polymer membranes for continuous analyte sensors | DexCom, Inc. (San Diego, CA) | See Plans and Pricing |
| Indobufen | See Plans and Pricing | Pyrazolyl-substituted heteroaryls and their use as medicaments | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Indobufen
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Indobufen | Austria | AT361024 | 2017-03-04 | See Plans and Pricing |
| Indobufen | Austria | AT474219 | 2017-03-04 | See Plans and Pricing |
| Indobufen | Austria | AT480761 | 2017-03-04 | See Plans and Pricing |
| Indobufen | Austria | AT494018 | 2017-03-04 | See Plans and Pricing |
| Indobufen | Austria | AT548971 | 2017-03-04 | See Plans and Pricing |
| Indobufen | Australia | AU2003229330 | 2017-03-04 | See Plans and Pricing |
| Indobufen | Australia | AU2007303239 | 2017-03-04 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
